BIOMAT Database Logo BIOMAT Database Logo

[The monoamine oxidase inhibitors in cardiovascular therapeutics (angina pectoris and arterial hypertension)]. 1960

A ABAZA, and P A RUTLISBERGER

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D002319 Cardiovascular System The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body. Circulatory System,Cardiovascular Systems,Circulatory Systems
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000787 Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION. Angor Pectoris,Stenocardia,Stenocardias

Related Publications

A ABAZA, and P A RUTLISBERGER
[ANGINA PECTORIS AND MONOAMINE OXIDASE INHIBITORS].
August 1963, Bruxelles medical,
A ABAZA, and P A RUTLISBERGER
Monoamine oxidase inhibitors and angina pectoris.
February 1960, Angiology,
A ABAZA, and P A RUTLISBERGER
[Monoamine oxidase inhibitors in the treatment of angina pectoris].
December 1961, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
A ABAZA, and P A RUTLISBERGER
[Monoamine oxidase inhibitors in the treatment of angina pectoris].
November 1961, Orvosi hetilap,
A ABAZA, and P A RUTLISBERGER
Monoamine oxidase inhibitors in the treatment of angina pectoris.
February 1960, Angiology,
A ABAZA, and P A RUTLISBERGER
[TREATMENT OF ANGINA PECTORIS WITH MONOAMINE OXIDASE INHIBITORS].
January 1965, Das Deutsche Gesundheitswesen,
A ABAZA, and P A RUTLISBERGER
Present status of monoamine oxidase inhibitors in angina pectoris.
April 1965, Revista de investigacion,
A ABAZA, and P A RUTLISBERGER
[On the action of monoamine oxidase inhibitors in angina pectoris].
January 1962, Chemotherapia,
A ABAZA, and P A RUTLISBERGER
[On the treatment of angina pectoris with monoamine oxidase inhibitors].
May 1963, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
A ABAZA, and P A RUTLISBERGER
The use of monoamine oxidase inhibitors as adjuncts in the treatment of hypertension and angina pectoris.
December 1960, The American journal of cardiology,
Copied contents to your clipboard!